Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (4): 621-624. doi: 10.19723/j.issn.1671-167X.2020.04.004

Previous Articles     Next Articles

A clinical analysis of 14 cases of prostatic stromal tumor of uncertain malignant potential

Yi LIU1,Zhi-jian LIU1,Qi SHEN1,Jing-yun WU2,Yu FAN1,De-run LI1,Wei YU1,Zhi-song HE1,()   

  1. 1. Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Cancer Center, Beijing 100034, China
    2. Department of Radiology, Peking University First Hospital, Beijing 100034, China
  • Received:2020-03-31 Online:2020-08-18 Published:2020-08-06
  • Contact: Zhi-song HE E-mail:hezhisong901@163.com

RICH HTML

  

Abstract:

Objective: To investigate the clinical and pathologic characteristics, diagnosis, treatment, prognosis and survival of prostatic stromal tumor of uncertain malignant potential. Methods: Overall 14 patients with prostatic stromal tumor of uncertain malignant potential were treated from October 2008 to April 2020, the patient age ranged from 27 to 78 years (mean 54 years). The disease duration was 1 to 180 months (mean duration of 46 months). The clinical manifestations mainly included urinary obstructive symptoms and urethral irritating symptoms. The tumors were located in the peripheral zone or the transition zone. Digital rectum examination indicated prostatic tumor. Serum prostatic specific antigen level was always normal or elevated. Transrectal ultrasonography and magnetic resonance imaging indicated prostatic tumor. Magnetic resonance imaging in showed large, round, well-defined masses, which were diffusely heterogeneous signal on T2 weighted imaging. Following the administration of intravenous contrast medium, the lesion had diffuse and heterogeneous enhancement. Results: In the study, 3 cases underwent prostate biopsy, 2 cases underwent transurethral resection of the prostate, 9 cases underwent radical excision or transurethral resection of the prostate with definite diagnosis of pathologic features. Under the light microscope, the interstitial cells of stromal tumor of uncertain malignant potential were overgrowth and fusiform cells showed some degree of pleomorphism, nuclei with few mitotic figures, and necrosis was not often seen. Immunohistochemical staining showed that prostate specific antigen was negative, while vimentin was positive in the tumor tissue, CD34, progesterone receptor and smooth muscle actin were positive in the majority, and Ki67 positive index was 1%-20% (mean 6%). Twelve cases were followed-up, and the time of survival varied from 10 to 96 months (mean 65 months), two cases were lost to the follow-up, one case died of disease at the end of 10 months, nine cases were free of disease recurrence after surgery, two cases underwent more transurethral resection of the prostate due to local recurrence. Conclusion: STUMP is a very rare tumor of the specialized prostatic stroma with an unpredictable clinical behavior. The clinical manifestations, transrectal ultrasonography and magnetic resonance imaging are valuable for the diagnosis of prostatic stromal tumor of uncertain malignant potential. Its definite diagnosis depends on pathological examination. Up to now, early surgery and combined therapy are effective treatments for prostatic stromal tumor of uncertain malignant potential.

Key words: Prostatic neoplasms, Stromal tumor of uncertain malignant potential, Pathology

CLC Number: 

  • R737.25

Figure 1

Imaging appearance of stromal tumor of uncertain malignant potential A, transrectal ultrasonography showed a large, round, well-defined mass rooted in the transitional zone of the prostate; B, the MRI features were diffusely heterogeneous signal on T2 weighted imaging; C, following the administration of intravenous contrast medium, the lesion had diffuse and early enhancement."

Figure 2

Microscopically pathological features of stromal tumor of uncertain malignant potential A, stromal tumor of uncertain malignant potential revealed hypercellular stroma, cells showed some degree of pleomorphism, nuclei with few nitotic figures(HE ×100); B, vimentin were positive(IHC ×100); C, CD34 were positive(IHC ×100)."

[1] Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases[J]. Am J Surg Pathol, 1998,22(2):148-162.
pmid: 9500215
[2] Herawi M, Epstein JI. Specialized stromal tumors of the peostate: a clinicopathologic study of 50 cases[J]. Am J Surg Pathol, 2006,30(6):694-704.
doi: 10.1097/00000478-200606000-00004 pmid: 16723846
[3] 李超, 王慕文. 恶性潜能未定的前列腺间质肿瘤的临床特点及诊疗策略[J]. 泌尿外科杂志(电子版), 2013,5(4):25-27.
[4] Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: postate and bladder tumours[J]. Eur Urol, 2016,70(1):106-119.
pmid: 26996659
[5] Murer LM, Talmon GA. Stromal tumor of uncertain malignant potential of the prostate[J]. Arch Pathol Lab Med, 2014,138(1):1542-1545.
[6] Muglia VF, Saber G, Maggioni G, et al. MRI findings of prostate stromal tumor of uncertain malignant potential: a case report[J]. Br J Radiol, 2011,84(1006):e194-e196.
pmid: 21933974
[7] Shabaik A. Nonepithelial tumors and tumor-like lesions of the prostate gland[J]. Crit Rev Clin Lab Sci, 2003,40(4):429-472.
doi: 10.1080/10408360390247823 pmid: 14582603
[8] Tavora F, Kryvenko ON, Epstein JI. Mesenchymal tumours of the bladder and prostate: an update[J]. Pathology, 2013,45(2):104-115.
doi: 10.1097/PAT.0b013e32835c768b pmid: 23250042
[1] Zhicun LI, Tianyu WU, Lei LIANG, Yu FAN, Yisen MENG, Qian ZHANG. Risk factors analysis and nomogram model construction of postoperative pathological upgrade of prostate cancer patients with single core positive biopsy [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 896-901.
[2] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[3] Yuxuan TIAN,Mingjian RUAN,Yi LIU,Derun LI,Jingyun WU,Qi SHEN,Yu FAN,Jie JIN. Predictive effect of the dual-parametric MRI modified maximum diameter of the lesions with PI-RADS 4 and 5 on the clinically significant prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 567-574.
[4] Kaifeng YAO,Mingjian RUAN,Derun LI,Yuxuan TIAN,Yuke CHEN,Yu FAN,Yi LIU. Diagnostic efficacy of targeted biopsy combined with regional systematic biopsy in prostate cancer in patients with PI-RADS 4-5 [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 575-581.
[5] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[6] Yi LIU,Chang-wei YUAN,Jing-yun WU,Qi SHEN,Jiang-xi XIAO,Zheng ZHAO,Xiao-ying WANG,Xue-song LI,Zhi-song HE,Li-qun ZHOU. Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5 [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 812-817.
[7] Chang-wei YUAN,De-run LI,Zhi-hua LI,Yi LIU,Gang-zhi SHAN,Xue-song LI,Li-qun ZHOU. Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 838-842.
[8] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
[9] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[10] Wei-hua HOU,Shu-jie SONG,Zhong-yue SHI,Mu-lan JIN. Clinicopathological features of Helicobacter pylori-negative early gastric cancer [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 292-298.
[11] Xue-mei HA,Yong-zheng YAO,Li-hua SUN,Chun-yang XIN,Yan XIONG. Solid placental transmogrification of the lung: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 357-361.
[12] Bo-han NING,Qing-xia ZHANG,Hui YANG,Ying DONG. Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 366-369.
[13] Qian SU,Xin PENG,Chuan-xiang ZHOU,Guang-yan YU. Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 13-21.
[14] Er-shu BO,Peng HONG,Yu ZHANG,Shao-hui DENG,Li-yuan GE,Min LU,Nan LI,Lu-lin MA,Shu-dong ZHANG. Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 615-620.
[15] LI Bing-yu,TANG Zu-nan,HU Lei-hao,ZHANG Wen-bo,YU Yao,YU Guang-yan,PENG Xin. Clinicopathologic analysis of micro and mini parotid gland tumors [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 335-339.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!